Search results
Jul 2, 2024 · Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
- About
About us Sobi is a specialised international...
- Disease areas
Swedish; Therapeutic areas. Haematology. Haemophilia....
- Key medicines
Swedish; Medicines. Please note that the medicines mentioned...
- Stories
Swedish; Stories. Patients and science lie at the heart of...
- Sustainability
Sobi's main contribution to the global sustainable...
- Careers
At Sobi, we are transforming the lives of people living with...
- Investors
Sobi is a specialised international biopharmaceutical...
- Media
Media | Press releases Press releases 3 July, 2024 14:00...
- About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden. In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.
Jun 20, 2024 · SOBI | Complete Swedish Orphan Biovitrum AB stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
4 days ago · Stock analysis for Swedish Orphan Biovitrum AB (SOBI:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
- 1.8K
Feb 24, 2023 · Efanesoctocog alfa is a novel factor VIII therapy that provides high and sustained factor activity levels for a week with once-weekly dosing. It is the first and only haemophilia A treatment that can achieve near-normal factor activity levels and reduce bleeding episodes.
1 day ago · Swedish Orphan Biovitrum AB has an analyst consensus of Strong Buy, with a price target consensus of SEK332.50, representing a 17.99% upside. In a report released on June 28, RBC Capital also ...
Find the latest Swedish Orphan Biovitrum AB (publ) (BIOVF) stock quote, history, news and other vital information to help you with your stock trading and investing.
